Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
9 "Sang-Cheol Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Special Article
Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients
Jung Hye Kwon, Sang-Cheol Lee, Myung Ah Lee, Yu Jung Kim, Jung Hun Kang, Jin Young Kim, Hyo Jin Lee, Woo Kyun Bae, Mi-Jung Kim, Eui Kyu Chie, Jin Kim, Yeul Hong Kim, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2019;51(3):851-860.   Published online June 7, 2019
DOI: https://doi.org/10.4143/crt.2019.137
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
A cross-sectional survey was conducted to explore the current awareness and use of complementary and alternative medicine (CAM), as well as attitudes toward CAM, in patients with cancer and their family members in South Korea.
Materials and Methods
Between September 21 and October 31, 2017, a 25-item questionnaire regarding CAM experiences among cancer patients and their family members was conducted in 10 oncology clinics in South Korea after institutional review board approval at each institution.
Results
In total, 283/310 patients were analyzed. The median age was 60 years, and 60% were male. Most of the patients were actively receiving anticancer treatment at the time of the survey. A total of 106 patients (37%) had experienced a median of two types (interquartile range, 1 to 3) of CAM. Belief in CAM (odds ratio [OR], 3.015; 95% confidence interval [CI], 1.611 to 5.640) and duration of disease (OR, 1.012; 95% CI, 1.004 to 1.020) were independent factors for using CAM in multivariable analysis. Belief in CAM was significantly associated with current use of CAM (OR, 3.633; 95% CI, 1.567 to 8.424). Lay referral was the most common reason for deciding to use CAM, and only 25% of patients (72/283) discussed CAM with their physicians.
Conclusion
Patient attitudes toward and confidence in CAM modalities were strongly associated with their CAM experiences, and only a small number of patients had an open discussion about CAM with their physicians. A patient education program for CAM is needed.

Citations

Citations to this article as recorded by  
  • Bridging the gap: attitudes and practices toward complementary and alternative medicine among oncology patients and healthcare professionals in Croatia
    Ljerka Armano, Vanja Vasiljev, Tomislav Rukavina, Denis Juraga, Aleksandar Racz, Vanja Tešić
    Frontiers in Psychology.2025;[Epub]     CrossRef
  • The Relationship Between Cancer Patients’ Supportive Care Needs and Their Attitudes Toward Complementary and Alternative Medicine
    H Çelik, H Aslan
    Nigerian Journal of Clinical Practice.2024; 27(4): 415.     CrossRef
  • Complementary and alternative medicine use and its impact on quality of life among cancer patients in Freetown, Sierra Leone: considerations for a resource-limited setting
    Onome T. Abiri, Matilda Seinya Sheriff, Isaac O. Smalle, Nellie V.T. Bell, Ibrahim Franklyn Kamara, Thaim B. Kamara, Constance Cummings-John, Joshua Coker, Abdulai Jawo Bah, Joseph Sam Kanu, Ronita Luke, Lannes Kamara, John Smith, Mohamed Samai
    Discover Medicine.2024;[Epub]     CrossRef
  • Cancer care beyond the conventional: Challenges of integrative oncology in India
    Parvathy Venate, Vitthal G. Huddar
    Ayush Journal of Integrative Oncology.2024; 1(3 & 4): 35.     CrossRef
  • Alternative and complementary medicine in neurological disorders and neurological disability patients: Prevalence, factors, opinions and reasons
    Paul Carrillo-Mora, Marlene A. Rodríguez-Barragán, Jimena Quinzaños-Fresnedo, María del Refugio Pacheco-Gallegos, María Soto-Lara, Monserrat Velázquez-Ortega, María Fernanda Villarreal-Azamar, Ilse Jocelyn Aguirre-Medina, Mariana Rubalcava-Gracia-Medrano
    Complementary Therapies in Medicine.2023; 72: 102920.     CrossRef
  • Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
    Jung Sun Kim, Jung Hye Kwon, Sun Young Rha, Sang-Cheol Lee, Yoon Jung Chang, In-Sun Kwon, Kyung Han You, Ho Young Yoon
    Cancer Research and Treatment.2023; 55(2): 442.     CrossRef
  • Effects of COVID-19 fear and anxiety on attitudes towards complementary and alternative medicine use in women with gynecological cancer during the COVID-19 pandemic
    Fatma Uslu-Sahan, Ilknur Yesilcınar, Gonul Kurt, Elif Hancer, Gulten Guvenc
    Journal of Integrative Medicine.2023; 21(4): 377.     CrossRef
  • Use of Complementary and Alternative Medicine for Prostate Cancer among African Americans, African Immigrants and Caribbean Immigrants
    Nipher Malika, Lisa Roberts, Carlos Casiano, Susanne Montgomery
    Journal of Community Health.2022; 47(2): 284.     CrossRef
  • Traditional and complementary medicine use among cancer patients in Nepal: a cross-sectional survey
    Soo Jeung Choi, Sangita Karki Kunwor, Hyea Bin Im, Jung Hye Hwang, Dain Choi, Dongwoon Han
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • The effect of cancer on traditional, complementary and alternative medicine utilization in Korea: a fixed effect analysis using Korea Health Panel data
    Dongsu Kim, Soo-Hyun Sung, Seungwon Shin, Minjung Park
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • Use of Complementary and Alternative Medicine (CAM) in Patients With Colorectal Cancer
    Jeongwon Yeom, Jung Mi Lee
    Clinical Nutrition Research.2022; 11(4): 255.     CrossRef
  • Cancer Research Trends in Traditional Korean Medical Journals since 2000 - Topic Modeling Using Latent Dirichlet Allocation and Keyword Network Analysis
    Kyeore Bae
    The Journal of Internal Korean Medicine.2022; 43(6): 1075.     CrossRef
  • Borders between integrative medicine and EBM: significance, potential for use and legal issues in European Union member states. Narrative review
    Aneta Brygida Jędrzejewska, Barbara Janina Ślusarska, Grzegorz Józef Nowicki
    Pielegniarstwo XXI wieku / Nursing in the 21st Century.2022; 21(2): 122.     CrossRef
  • Evaluation of outpatient cancer patients’ use of nonpharmacological methods in the management of chemotherapy-induced nausea and vomiting
    Eda ERGİN, Tülay SAĞKAL MİDİLLİ, Eda AKDAĞ, Ceyda KIRGÖZ
    Cukurova Medical Journal.2021; 46(2): 574.     CrossRef
  • The Current Status of Integrative Oncology in Korea
    Eun-Bin Kwag, Soo-Dam Kim, Ji Hye Park, So-Jung Park, Mi-Kyung Jeong, Hwa-Seung Yoo
    Integrative Cancer Therapies.2021;[Epub]     CrossRef
  • Biologically-Based Complementary and Alternative Medicine (CAM) Use in Cancer Patients: The Good, the Bad, the Misunderstood
    Kathryn Knecht, David Kinder, Amy Stockert
    Frontiers in Nutrition.2020;[Epub]     CrossRef
  • Efficacy of Chemotherapy Integrated With Traditional Korean Medicine in Patients With Metastatic Pancreatic Cancer: A Single-Center Retrospective Study
    Eun Hye Kim, Jee-Hyun Yoon, Sung Soo Yoon, Jee Young Lee, Seong Woo Yoon
    Integrative Cancer Therapies.2020;[Epub]     CrossRef
  • 9,538 View
  • 228 Download
  • 15 Web of Science
  • 17 Crossref
Close layer
Original Article
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study
So-Yeon Jeon, Hye Sook Han, Woo Kyun Bae, Moo-Rim Park, Hyeok Shim, Sang-Cheol Lee, Se-Il Go, Hwan Jung Yun, Yong-Jin Im, Eun-Kee Song
Cancer Res Treat. 2019;51(1):90-97.   Published online February 27, 2018
DOI: https://doi.org/10.4143/crt.2017.577
AbstractAbstract PDFPubReaderePub
Purpose
Data on the efficacy of olanzapine in patients receiving moderately emetogenic chemotherapy (MEC) are limited. This study aimed to evaluate and compare the efficacy of olanzapine versus placebo in controlling nausea and vomiting in patients receiving MEC.
Materials and Methods
We conducted a randomized, double-blind, placebo-controlled study to determine whether olanzapine can reduce the frequency of chemotherapy-induced nausea and vomiting (CINV) and improve the quality of life (QOL) in patients receiving palonosetron and dexamethasone as prophylaxis for MEC-induced nausea and vomiting. The primary end point was complete response for the acute phase (0-24 hours after chemotherapy). The secondary end points were complete response for the delayed (24-120 hours) and overall phase (0-120 hours), proportion of significant nausea (visual analogue scale ≥ 25 mm), use ofrescue medications, and effect on QOL.
Results
Fifty-six patients were randomized to the olanzapine (n=29) and placebo (n=27) groups. Complete response rates were not significantly different between the olanzapine and placebo groups in the acute (96.5% vs. 88.0%, p=0.326), delayed (69.0% vs. 48.0%, p=0.118), and overall phases (69.0% vs. 48.0%, p=0.118). However, the percentage of patients with significant nausea (17.2% vs. 44.0%, p=0.032) and the use of rescue medications (0.03±0.19 vs. 1.88±2.88, p=0.002) were lower in the olanzapine group than in the placebo. Furthermore, the olanzapine group demonstrated better QOL (p=0.015).
Conclusion
Olanzapine combined with palonosetron and dexamethasone significantly improved QOL and vomiting control among previously untreated patients receiving MEC, although the efficacy was limited to the reduction of the frequency of CINV.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology
    Kazuhisa Nakashima, Saki Harashima, Rena Kaneko, Ryuhei Tanaka, Masakazu Abe, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Eriko Satomi, Masayuki Takeda, Takako Eguchi Nakajima, Naoki
    International Journal of Clinical Oncology.2025; 30(1): 17.     CrossRef
  • 2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients
    Samantha K. F. Kennedy, Shannon Goodall, Shing Fung Lee, Carlo DeAngelis, Allison Jocko, Flay Charbonneau, Katie Wang, Mark Pasetka, Yoo-Joung Ko, Henry C. Y. Wong, Adrian Wai Chan, Thenugaa Rajeswaran, Milena Gojsevic, Edward Chow, Richard J. Gralla, Ter
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy
    Jing Shen, Juan Zhao, Gaowa Jin, Hui Li, Ying Jiang, Yungaowa Wu, Jiali Gao, Feng Chen, Jiaxuan Li, Wenjuan Wang, Quanfu Li
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Health-Related Quality of Life and Economic Analysis of Olanzapine Versus Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Malaysia
    Nurul Suhaida Badarudin, Noraida Mohamed Shah, Nurul Ain Mohd Tahir, Azmi Nor Mohd Farez Ahmat, Fuad Ismail, Farida Islahudin, Suhana Yusak, Syahir Muhammad, Kamarun Neasa Begam Mohd Kassim
    Value in Health Regional Issues.2024; 44: 101028.     CrossRef
  • Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy
    Vikas Ostwal, Anant Ramaswamy, Sarika Mandavkar, Prabhat Bhargava, Deepali Naughane, Sharon Flavia Sunn, Sujay Srinivas, Akhil Kapoor, Bal Krishna Mishra, Anuj Gupta, Bipinesh Sansar, Vikash Pal, Aparajita Pandey, Avinash Bonda, Indraja Siripurapu, Vamshi
    JAMA Network Open.2024; 7(8): e2426076.     CrossRef
  • Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clin
    Kazuhisa Nakashima, Ayako Yokomizo, Michiyasu Murakami, Kenji Okita, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Hidenori Sasaki, Eriko Satomi, Masayuki Takeda, Ryuhei Tanaka, Takako
    International Journal of Clinical Oncology.2024; 29(12): 1785.     CrossRef
  • Can olanzapine preserve life quality in cancer patients undergoing abdominal radiation therapy?
    Meenu Vijayan, Sherin Joseph, Haridas M Nair, Debnarayan Dutta, M.P. Narmadha
    Medical Hypotheses.2023; 171: 111014.     CrossRef
  • Chemotherapy: how to reduce its adverse effects while maintaining the potency?
    Brianna, Sau Har Lee
    Medical Oncology.2023;[Epub]     CrossRef
  • The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
    Aziz Eghbali, Tahereh Bagherloo, Ali Ghasemi, Roghayeh R. Afzal, Aygin Eghbali, Kazem Ghaffari
    Advanced Biomedical Research.2023;[Epub]     CrossRef
  • Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience
    Akihiro Uchiike, Haruka Kono, Katsuhiro Miura, Tatsuya Hayama, Daisuke Tsutsumi, Shinya Tsuboi, Susumu Ohtsuka, Shinji Hidaka
    Journal of Pharmaceutical Health Care and Sciences.2023;[Epub]     CrossRef
  • Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study
    Rony Dev, Linda L. Zhong, Abdulrazzak Zarifa, Aya A. Albittar, Laura Rubin, Suyu Liu, Timothy A. Yap, Shalini Dalal, David Hui, Daniel D. Karp, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Jordi Rodon Ahnert, Siqing Fu, Funda Meric-Bernstam, Aung Naing
    Investigational New Drugs.2022; 40(1): 124.     CrossRef
  • Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis
    Priya Patel, Paula D. Robinson, Nora Wahib, Patrick Cheung, Thomas Wong, Sandra Cabral, Arden Parker, Marie Cohen, Katie Devine, Paul Gibson, Mark T. Holdsworth, Eloise Neumann, Andrea Orsey, Robert Phillips, Daniela Spinelli, Jennifer Thackray, Marianne
    Supportive Care in Cancer.2022; 30(11): 8855.     CrossRef
  • Ջոակինո Ռոսինիի «Stabat Mater»-ը Հովհաննես Չեքիջյանի մեկնաբանությամբ (նվիրվում է Ռոսինիի «Stabat Mater»-ի ստեղծման 180-ամյակին և Հայաստանի ազգային ակադեմիական երգչախմբի հիմնադրման 85-ամյակին)
    Աննա Ասատրյան
    Journal of Art Studies.2022; : 79.     CrossRef
  • Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial
    Maurice J.D.L. van der Vorst, Elisa C. Toffoli, Marlien Beusink, Myra E. van Linde, Theo van Voorthuizen, Saskia Brouwer, Annette A. van Zweeden, Suzan Vrijaldenhoven, Johan C. Berends, Johannes Berkhof, Henk M.W. Verheul
    The Oncologist.2021; 26(1): e173.     CrossRef
  • Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature
    Ronald Chow, Jørn Herrstedt, Matti Aapro, Leonard Chiu, Henry Lam, Elizabeth Prsic, Michael Lock, Carlo DeAngelis, Rudolph M. Navari
    Supportive Care in Cancer.2021; 29(7): 3439.     CrossRef
  • A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients
    Junichi Nishimura, Akiko Hasegawa, Toshihiro Kudo, Tomoyuki Otsuka, Masayoshi Yasui, Chu Matsuda, Naotsugu Haraguchi, Hajime Ushigome, Nozomu Nakai, Tomoki Abe, Hisashi Hara, Naoki Shinno, Kei Asukai, Shinichiro Hasegawa, Daisaku Yamada, Keijiro Sugimura,
    Scientific Reports.2021;[Epub]     CrossRef
  • The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis
    Dong-Yang Wang, Yi Chen, You Zhang, Ying-Qiang Shen
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
    Winnie Yeo, Thomas KH. Lau, Leung Li, Kwai Tung Lai, Elizabeth Pang, Maggie Cheung, Vicky TC. Chan, Ashley Wong, Winnie MT. Soo, Vanessa TY. Yeung, Teresa Tse, Daisy CM. Lam, Eva WM. Yeung, Kim PK. Ng, Nelson LS. Tang, Macy Tong, Joyce JS. Suen, Frankie K
    The Breast.2020; 50: 30.     CrossRef
  • RETRACTED ARTICLE: Poloxamer-407-Co-Poly (2-Acrylamido-2-Methylpropane Sulfonic Acid) Cross-linked Nanogels for Solubility Enhancement of Olanzapine: Synthesis, Characterization, and Toxicity Evaluation
    Kifayat Ullah Khan, Naveed Akhtar, Muhammad Usman Minhas
    AAPS PharmSciTech.2020;[Epub]     CrossRef
  • Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study


    Xuan Wu, Jingxun Wu, Gangling Tong, Boran Cheng, Minhua Chen, Shaokang Yu, Lirui He, Zhu Li, Shubin Wang
    Cancer Management and Research.2020; Volume 12: 6575.     CrossRef
  • Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
    So Rae Lee, Su Min Kim, Min Young Oh, Jae Min Lee
    Children.2020; 7(9): 140.     CrossRef
  • Olanzapine: The Game-Changer “Antiemetic”
    Manikandan Dhanushkodi
    Indian Journal of Medical and Paediatric Oncology.2019; 40(02): 274.     CrossRef
  • 9,657 View
  • 496 Download
  • 24 Web of Science
  • 22 Crossref
Close layer
Case Report
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
Won-Young Park, Han-Jo Kim, Kyoungha Kim, Sang-Byung Bae, Namsu Lee, Kyu-Taek Lee, Jong-Ho Won, Hee-Sook Park, Sang-Cheol Lee
Cancer Res Treat. 2016;48(2):843-847.   Published online March 2, 2015
DOI: https://doi.org/10.4143/crt.2014.234
AbstractAbstract PDFPubReaderePub
Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive (HER2+) breast cancer following IT trastuzumab for leptomeningeal carcinomatosis. The first patient was treated with weekly IT 15 mg methotrexate plus IT 50 mg trastuzumab for 7 months, followed by IT trastuzumab (50 mg > 25 mg) for 18 months. The other patient received IT trastuzumab with systemic chemotherapy (trastuzumab and/or paclitaxel) for 13 months. Good control of leptomeningeal disease was achieved with IT trastuzumab in both patients, with survival durations of 20 and 29 months, respectively. We suggest that IT trastuzumab is a promising treatment for patients with HER2+ breast cancer and leptomeningeal carcinomatosis.

Citations

Citations to this article as recorded by  
  • The research progress on meningeal metastasis in solid tumors
    Yi Yue, Yuqing Ren, Chunya Lu, Nan Jiang, Sihui Wang, Junkai Fu, Mengrui Kong, Guojun Zhang
    Discover Oncology.2025;[Epub]     CrossRef
  • An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
    Mainak Bardhan, Debankur Dey, Vinay Suresh, Binish Javed, Vyshak Alva Venur, Neha Joe, Ritvika Kalidindi, Ahmad Ozair, Marium Khan, Reshma Mahtani, Simon Lo, Yazmin Odia, Manmeet S. Ahluwalia
    Expert Review of Neurotherapeutics.2024; 24(1): 77.     CrossRef
  • Intrathecal Trastuzumab for HER2-Positive Cancer of Unknown Primary Leptomeningeal Metastasis: A Case Report
    Kohei Oka, Shun Futamura, Taishi Harada
    Cureus.2024;[Epub]     CrossRef
  • A Review on the Efficacy and Safety of Intrathecal Administration of Novel Medications for Leptomeningeal Metastases in Solid Cancers
    Fatemeh Jafari, Mohammad Moeini Nodeh, Hesamoddin Hosseinjani, Hamed Baharara, Sajad Azad, Omid Arasteh, Thomas P. Johnston, Amirhossein Sahebkar
    Current Medicinal Chemistry.2024; 31(19): 2732.     CrossRef
  • Leptomeningeal Carcinomatosis from Solid Tumor Malignancies: Treatment Strategies and Biomarkers
    Rachna Malani, Ankush Bhatia, Allison Betof Warner, Jonathan T. Yang
    Seminars in Neurology.2023; 43(06): 859.     CrossRef
  • Leptomeningeal metastases: the future is now
    Rimas V. Lukas, Jigisha P. Thakkar, Massimo Cristofanilli, Sunandana Chandra, Jeffrey A. Sosman, Jyoti D. Patel, Priya Kumthekar, Roger Stupp, Maciej S. Lesniak
    Journal of Neuro-Oncology.2022; 156(3): 443.     CrossRef
  • Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
    Yajing Chi, Mao Shang, Liang Xu, Heyi Gong, Rongjie Tao, Lihua Song, Baoxuan Zhang, Sha Yin, Binbin Cong, Huihui Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression
    Flora Zagouri, Panagiotis Zoumpourlis, Emilie Le Rhun, Rupert Bartsch, Eleni Zografos, Kleoniki Apostolidou, Meletios-Athanasios Dimopoulos, Matthias Preusser
    Cancer Treatment Reviews.2020; 88: 102046.     CrossRef
  • Leptomeningeal carcinomatosis in patients with breast cancer
    Maria Alice Franzoi, Gabriel N. Hortobagyi
    Critical Reviews in Oncology/Hematology.2019; 135: 85.     CrossRef
  • Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy
    Nicholas B. Figura, Victoria T. Rizk, Homan Mohammadi, Brittany Evernden, Sepideh Mokhtari, H. Michael Yu, Timothy J. Robinson, Arnold B. Etame, Nam D. Tran, James Liu, Iman Washington, Roberto Diaz, Brian J. Czerniecki, Hatem Soliman, Hyo S. Han, Solmaz
    Breast Cancer Research and Treatment.2019; 175(3): 781.     CrossRef
  • Breast leptomeningeal disease: a review of current practices and updates on management
    Nicholas B. Figura, Victoria T. Rizk, Avan J. Armaghani, John A. Arrington, Arnold B. Etame, Hyo S. Han, Brian J. Czerniecki, Peter A. Forsyth, Kamran A. Ahmed
    Breast Cancer Research and Treatment.2019; 177(2): 277.     CrossRef
  • Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
    Kelsey M Bowman, Priya Kumthekar
    Future Oncology.2018; 14(4): 391.     CrossRef
  • Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience
    Nicholas B. Figura, Wendy Long, Michael Yu, Timothy J. Robinson, Sepideh Mokhtari, Arnold B. Etame, Nam D. Tran, Roberto Diaz, Hatem Soliman, Heather S. Han, Solmaz Sahebjam, Peter A. Forsyth, Kamran A. Ahmed
    Breast Cancer Research and Treatment.2018; 169(2): 391.     CrossRef
  • Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
    Niyanta N. Kumar, Michelle E. Pizzo, Geetika Nehra, Brynna Wilken-Resman, Sam Boroumand, Robert G. Thorne
    Bioconjugate Chemistry.2018; 29(12): 3937.     CrossRef
  • Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
    J. Remon, E. Le Rhun, B. Besse
    Cancer Treatment Reviews.2017; 53: 128.     CrossRef
  • Current challenges in the management of breast cancer brain metastases
    Ciara C. O’Sullivan, Nicole N. Davarpanah, Jame Abraham, Susan E. Bates
    Seminars in Oncology.2017; 44(2): 85.     CrossRef
  • Leptomeningeal disease: current diagnostic and therapeutic strategies
    Gautam Nayar, Tiffany Ejikeme, Pakawat Chongsathidkiet, Aladine A. Elsamadicy, Kimberly L. Blackwell, Jeffrey M. Clarke, Shivanand P. Lad, Peter E. Fecci
    Oncotarget.2017; 8(42): 73312.     CrossRef
  • Leptomeningeal metastases of solid cancer
    Emilie Le Rhun, Evanthia Galanis
    Current Opinion in Neurology.2016; 29(6): 797.     CrossRef
  • Metastatic breast cancer: The Odyssey of personalization
    A. Sonnenblick, N. Pondé, M. Piccart
    Molecular Oncology.2016; 10(8): 1147.     CrossRef
  • Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
    Eleonora Teplinsky, Francisco J. Esteva
    Current Oncology Reports.2015;[Epub]     CrossRef
  • 16,489 View
  • 191 Download
  • 21 Web of Science
  • 20 Crossref
Close layer
Original Articles
Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line
Suk-Gu Yoon, Hee-Jeong Cheong, Sook-Ja Kim, Kyoung Ha Kim, Sang-Cheol Lee, Namsu Lee, Hee Sook Park, Jong-Ho Won
Cancer Res Treat. 2013;45(2):126-133.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.126
AbstractAbstract PDFPubReaderePub
PURPOSE
Leukemic promyelocytes have the unique ability to undergo differentiation after exposure to retinoic acid and both differentiation and apoptosis after exposure to arsenic trioxide (ATO). Recent studies have shown that inhibition of Src family kinases (SFKs) resulted in enhancement of retinoic acid-induced myeloid differentiation.
MATERIALS AND METHODS
In this study, we investigated the question of whether the SFK inhibitor PP2 enhanced the differentiation of NB4 cells when combined with ATO as well as when combined with all-trans-retinoic acid (ATRA). In addition, we attempted to determine the difference in retinoic acid-induced gene expression between cells treated with PP2 in combination with ATRA and in combination with ATO.
RESULTS
SFK inhibitor PP2 induced significant enhancement of ATRA- or ATO-induced differentiation of NB4 cells. A significantly stronger synergistic effect was observed when PP2 was combined with ATRA than when combined with ATO. Flow cytometric analysis demonstrated a significant increase in CD11b-positive granulocytes up to 60.73% and 31.58%, respectively. These results were confirmed by nitroblue tetrazolium staining. These effects were not related to apoptosis. Results of Annexin-V-fluorescein staining revealed that PP2 combined with ATRA or PP2 combined with ATO did not induce apoptosis in NB4 cells. Retinoic acid-induced gene expression was different in both groups. Intercellular adhesion molecule-1 expression showed a significant increase in cells treated with PP2 in combination with ATRA, whereas cathepsin D expression showed a significant increase in cells treated with PP2 in combination with ATO.
CONCLUSION
Our data showed that SFK inhibitor PP2 enhanced acute promyelocytic leukemia cell differentiation when combined with either ATRA or ATO with difference in activation of retinoic acid-induced genes.

Citations

Citations to this article as recorded by  
  • An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
    Yanan Jiang, Xiuyun Shen, Fengnan Zhi, Zhengchao Wen, Yang Gao, Juan Xu, Baofeng Yang, Yunlong Bai
    Cell Death Discovery.2023;[Epub]     CrossRef
  • Integrated bioinformatics analysis and network pharmacology to explore the potential mechanism of Patrinia heterophylla Bunge against acute promyelocytic leukemia
    Liya Feng, Sha Zhu, Jian Ma, Yali Hong, Meixia Wan, Qian Qiu, Hongjing Li, Juan Li
    Medicine.2023; 102(40): e35151.     CrossRef
  • Serum levels of FAK and some of its effectors in adult AML: correlation with prognostic factors and survival
    Mona G. El-Sisi, Sara M. Radwan, Alia M. Saeed, Hala O. El-Mesallamy
    Molecular and Cellular Biochemistry.2021; 476(5): 1949.     CrossRef
  • O-GlcNAc homeostasis contributes to cell fate decisions during hematopoiesis
    Zhen Zhang, Matthew P. Parker, Stefan Graw, Lesya V. Novikova, Halyna Fedosyuk, Joseph D. Fontes, Devin C. Koestler, Kenneth R. Peterson, Chad Slawson
    Journal of Biological Chemistry.2019; 294(4): 1363.     CrossRef
  • Src family kinases and their role in hematological malignancies
    Matthew Ku, Meaghan Wall, Ruth N. MacKinnon, Carl R. Walkley, Louise E. Purton, Constantine Tam, David Izon, Lynda Campbell, Heung-Chin Cheng, Harshal Nandurkar
    Leukemia & Lymphoma.2015; 56(3): 577.     CrossRef
  • Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells
    Ashleigh R. Poh, Robert J.J. O’Donoghue, Matthias Ernst
    Oncotarget.2015; 6(18): 15752.     CrossRef
  • Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide
    Yun Seok Jung, Hee-Jeong Cheong, Sook-Ja Kim, Kyoung Ha Kim, Namsu Lee, Hee Sook Park, Jong-Ho Won
    Leukemia Research.2014; 38(8): 977.     CrossRef
  • 11,591 View
  • 64 Download
  • 7 Crossref
Close layer
Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
Ji Yeon Kwon, Jina Yun, Han Jo Kim, Kyoung-Ha Kim, Se-Hyung Kim, Sang-Cheol Lee, Hyun Jung Kim, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Seong Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2011;43(4):244-249.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.244
AbstractAbstract PDFPubReaderePub
PURPOSE
The prognosis of gastric cancer patients with bone marrow metastases is extremely poor. The current study was conducted to evaluate the clinical outcomes of advanced gastric cancer patients with bone marrow metastases.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 26 advanced gastric cancer patients with bone marrow metastases who were treated at Soonchunhyang University Hospital between September 1986 and February 2009.
RESULTS
The median age was 46 years (range, 24 to 61 years). All patients had poorly differentiated adenocarcinoma, including 17 signet ring cell carcinomas. The majority of the patients had thrombocytopenia, anemia, and elevated lactate dehydrogenase levels. Sixteen patients (61.5%) received palliative chemotherapy (median, 4 cycles; range, 1 to 13 cycles). The median overall survival after detection of bone marrow metastases for the cohort of patients was 37 days (95% confidence interval, 12.5 to 61.5 days). The median overall survival after detection of bone marrow involvement was 11 days in the best supportive care group (range, 2 to 34 days) and 121 days (range, 3 to 383 days) in the palliative chemotherapy group (p<0.001). The causes of death were tumor progression (11 patients, 45%), brain hemorrhage (6 patients, 25%), infection (5 patients, 21%), and disseminated intravascular coagulation (1 patient, 4%). There were no chemotherapy-related deaths.
CONCLUSION
Palliative chemotherapy could be considered in advanced gastric cancer patients with bone marrow metastases as a treatment option.

Citations

Citations to this article as recorded by  
  • Bone marrow metastasis of ovarian cancer: A two‑center retrospective study and literature review
    Tomonori Yamada, Junya Nakajima, Yuuki Ooba, Akira Yabuno, Yuri Yano, Masaki Yoshida, Mitsutake Yano, Masanori Yasuda, Eiji Kobayashi
    Molecular and Clinical Oncology.2025;[Epub]     CrossRef
  • Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review
    Hirotaka Suto, Yumiko Inui, Atsuo Okamura
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Comprehensive review of solid tumor bone marrow metastasis
    Lanxin Zhang, Fengxi Chen, Lingzhi Xu, Ning Li, Qiping Zhuo, Yijin Guo, Xueqing Wang, Meijie Wen, Zuowei Zhao, Man Li
    Critical Reviews in Oncology/Hematology.2024; 194: 104248.     CrossRef
  • Mechanism and clinical progression of solid tumors bone marrow metastasis
    Ruohan Yang, Lin Jia, Jiuwei Cui
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Is Bone Marrow Metastasis in Gastric Cancer Adequate for Best Supportive Care Decisions? Or is There Still a Chance?
    Berkan Karabuğa, Ergin Aydemir, Fatih Yıldız, Necati Alkış
    Acta Haematologica Oncologica Turcica.2024;[Epub]     CrossRef
  • Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities
    Wen Ye, Liping He, Lei Su, Zhousan Zheng, Meilin Ding, Sheng Ye
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Bone Metastasis From Gastric Adenocarcinoma—What Are the Risk Factors and Associated Survival? A Large Comprehensive Population-Based Cohort Study
    Lei Huang, Yajie Zhao, Yan Shi, Weiguo Hu, Jun Zhang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Gastric Cancer With Multiple Bone Metastases: An Uncommon Primary Presentation
    João Barbosa-Martins, Salomé Marques, Olinda Miranda, Bárbara Lima, Jorge Cotter
    Cureus.2022;[Epub]     CrossRef
  • Docetaxel and Fluorouracil as First-Line Therapy for Gastric Cancer with Bone Marrow Metastasis and Disseminated Intravascular Coagulation
    Zhai Xiaohui, Li Shanshan, Cao Taiyuan, Du Ge, Yu Hongen, Shi Lishuo, Lin Xiaoru, Hong Wanjia, Xiao Jian
    Future Oncology.2022; 18(35): 3875.     CrossRef
  • The influence of serum sodium concentration on prognosis in patients with urothelial carcinoma treated by radical cystectomy
    Yan Zhang, Zuojun Wang, Xue Yang, Qingchun Zhao, Long He
    Medicine.2022; 101(52): e31973.     CrossRef
  • Access to Palliative Care Services and Clinical Outcomes of Patients With Solid Malignancy-Associated Myelophthisis in a Resource-Limited Setting
    Cesar Vargas-Serafin, Aldo A. Acosta-Medina, Kevin Teran-De-la-Sancha, Jesus Delgado-de-la-Mora, María T. Bourlon, Christianne Bourlon
    American Journal of Hospice and Palliative Medicine®.2021; 38(8): 932.     CrossRef
  • Disseminated Bone Marrow Carcinomatosis Due to Malignant Melanoma of Unknown Primary Origin
    Kotaro Matsumoto, Kentaro Kikuchi, Tomohiro Kikuyama, Go Saito, Takako Adachi, Ayako Watanabe, Hiromichi Tsunashima, Takayuki Tsujikawa, Ken Sato, Shinpei Doi
    Internal Medicine.2021; 60(21): 3469.     CrossRef
  • Survival Outcomes and Treatment Decision by Human Papillomavirus Status Among Patients With Stage IVC Head and Neck Squamous Cell Carcinoma
    Ping Zhou, Yi-Feng Yu, Chen-Lu Lian, Jun Wang, Ren-Gong Zhuo, San-Gang Wu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Gastric Signet Ring Cell Carcinoma with Metastasis to the Bone and Bone Marrow in a Patient with 12-Year-Disease-Free Interval and Unusually Long Survival Time
    Hyung Woo Kim, Mi Jin Gu, Jong Ho Lee
    Laboratory Medicine Online.2021; 11(4): 305.     CrossRef
  • Signet-ring cells in the bone marrow as an indication of cryptic metastasis of breast carcinoma
    Shuang Ma, Bruce D. Leckey Jr, Wan-Lin Zhang, Hong-Tao Xu, Lian-He Yang, Endi Wang
    Medicine.2019; 98(11): e14883.     CrossRef
  • Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study
    Giovanni Fucà, Luigi Mariani, Salvatore Lo Vullo, Giulia Galli, Rossana Berardi, Massimo Di Nicola, Claudio Vernieri, Daniele Morelli, Katia Dotti, Ilaria Fiordoliva, Silvia Rinaldi, Cecilia Gavazzi, Filippo Pietrantonio, Marco Platania, Filippo de Braud
    Scientific Reports.2019;[Epub]     CrossRef
  • Malignant Pleural Mesothelioma with Bone Marrow Metastases
    Hiroaki Ihara, Norihiro Harada, Naoko Shimada, Koichiro Kanamori, Takuo Hayashi, Toshimasa Uekusa, Kazuhisa Takahashi
    Internal Medicine.2018; 57(17): 2541.     CrossRef
  • An unusual hematological presentation of gastric adenocarcinoma
    Hendra Koncoro, Eddy Setijoso, Findy Prasetiawaty, Maisie ME Johan, Renaningtyas Tambun
    Gastroenterology & Hepatology: Open Access.2018;[Epub]     CrossRef
  • Clinical outcome of 30 patients with bone marrow metastases
    Min Hang Zhou, Zhi Hong Wang, Hong Wei Zhou, Mo Liu, Yong Jian Gu, Jun Zhong Sun
    Journal of Cancer Research and Therapeutics.2018; 14(Suppl 2): S512.     CrossRef
  • Recurrent gastric cancer metastasizing to the bone marrow: A case report of a rare presentation
    Ernest Fonocho, Nail Aydin, Srini Reddy, Subhasis Misra
    International Journal of Surgery Case Reports.2017; 37: 165.     CrossRef
  • Clinical Outcomes of Endoscopic Hemostasis for Bleeding in Patients with Unresectable Advanced Gastric Cancer
    In Ji Song, Hyun Ju Kim, Ji Ae Lee, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee, Hyunsoo Chung
    Journal of Gastric Cancer.2017; 17(4): 374.     CrossRef
  • Generalized high bone mineral density on bone density scanning: a case of gastric carcinoma with bone metastasis
    Pianpian Fan, Qin Wang, Chunyan Lu, Decai Chen
    Postgraduate Medicine.2017; 129(2): 299.     CrossRef
  • A case of disseminated carcinomatosis of the bone marrow originating from gastric cancer 3 years after intraperitoneal chemotherapy against peritoneal carcinomatosis
    Takayuki Okuno, Hironori Yamaguchi, Joji Kitayama, Hironori Ishigami, Takeshi Nishikawa, Junichiro Tanaka, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Kazushige Kawai, Shinsuke Kazama, Soichiro Ishihara, Eiji Sunami, Toshiaki Watan
    World Journal of Surgical Oncology.2016;[Epub]     CrossRef
  • Pathological findings in a case of bone marrow carcinosis due to gastric cancer complicated by disseminated intravascular coagulation and thrombotic microangiopathy
    Yoshinobu Seki, Kunihiko Wakaki
    International Journal of Hematology.2016; 104(4): 506.     CrossRef
  • Endoscopic Management of Tumor Bleeding from Inoperable Gastric Cancer
    Young-Il Kim, Il Ju Choi
    Clinical Endoscopy.2015; 48(2): 121.     CrossRef
  • An Unusual Case of Gastric Cancer with Bone Marrow Metastases and Embolic Phenomena as Initial Presentation
    Harjot Kaur, Appalanaidu Sasapu, Jeanette Ramos, Rangaswamy Govindarajan
    Journal of Gastrointestinal Cancer.2015; 46(4): 413.     CrossRef
  • Development and Validation of a Prognostic Score to Predict Survival in Adult Patients With Solid Tumors and Bone Marrow Metastases
    Wen-Chi Chou, Kun-Yun Yeh, Meng-Ting Peng, Jen-Shi Chen, Hung-Ming Wang, Yung-Chang Lin, Chien-Ting Liu, Shau-Hsuan Li, Pei-Hung Chang, Cheng-Hsu Wang, Ping-Tsung Chen, Yu-Shin Hung, Chang-Hsien Lu
    Medicine.2015; 94(23): e966.     CrossRef
  • Her-2 Positive Gastric Cancer Presented with Thrombocytopenia and Skin Involvement: A Case Report
    Deniz Arslan, Mukremin Uysal, Ali Murat Tatlı, Seyda Gunduz, Sema Sezgin Goksu, Cumhur İbrahim Başsorgun, Hasan Senol Coskun, Hakan Bozcuk, Burhan Savaş
    Case Reports in Oncological Medicine.2014; 2014: 1.     CrossRef
  • Gastric Carcinoma with Bone Marrow Metastasis: A Case Series
    Ahmet Şiyar Ekinci, Öznur Bal, Tahsin Özatlı, İbrahim Türker, Onur Eşbah, Ayşe Demirci, Burçin Budakoğlu, Ülkü Yalçıntaş Arslan, Emrah Eraslan, Berna Öksüzoğlu
    Journal of Gastric Cancer.2014; 14(1): 54.     CrossRef
  • Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis
    Yu Jung Kim, Se Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee
    European Journal of Cancer.2014; 50(16): 2810.     CrossRef
  • Methylated TIMP-3 DNA in Body Fluids Is an Independent Prognostic Factor for Gastric Cancer
    Jiang-Liu Yu, Ping Lv, Jing Han, Xin Zhu, Lian-Lian Hong, Wang-Yu Zhu, Xin-Bao Wang, Yi-Chen Wu, Pei Li, Zhi-Qiang Ling
    Archives of Pathology & Laboratory Medicine.2014; 138(11): 1466.     CrossRef
  • Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases
    Yu-Shin Hung, Wen-Chi Chou, Tai-Di Chen, Tse-Ching Chen, Po-Nan Wang, Hung Chang, Hung-Chih Hsu, Wen-Chi Shen, Wei-Hong Cheng, Jen-Shi Chen
    Asian Pacific Journal of Cancer Prevention.2014; 15(1): 61.     CrossRef
  • Preoperative serum pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen level predicts postoperative distant metastasis in patients with non-small-cell lung cancer†
    Yumi Tanaka, Tatsuya Yoshimasu, Shoji Oura, Yoshimitsu Hirai, Mitsumasa Kawago, Masako Ikeda, Yoshitaka Okamura
    European Journal of Cardio-Thoracic Surgery.2013; 44(3): 539.     CrossRef
  • 13,089 View
  • 105 Download
  • 33 Crossref
Close layer
Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
Han Jo Kim, Jun Young Eun, Young Woo Jeon, Jina Yun, Kyoung Ha Kim, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2011;43(3):154-159.   Published online September 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.3.154
AbstractAbstract PDFPubReaderePub
PURPOSE
We retrospectively determined the efficacy and safety of the combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line chemotherapy for patients with metastatic or recurrent gastric cancer.
MATERIALS AND METHODS
Between January 2006 and August 2009, 39 patients with histologically-confirmed, metastatic or recurrent gastric cancer underwent chemotherapy, and the results were retrospectively investigated. The chemotherapy regimen consisted of oxaliplatin (100 mg/m2) and FA (200 mg/m2; 2-hour infusion), then 5-FU (2,400 mg/m2; 46-hour continuous infusion) every 2 weeks.
RESULTS
Thirty-nine patients received a total of 210 treatment cycles. The median number of cycles was 6 (range, 1 to 16). Of the 32 evaluable patients, zero patients achieved a complete response and 11 patients achieved a partial response (response rate, 28.2%). The median time-to-progression and overall survival were 4.3 months (95% confidence interval [CI], 2.0 to 6.5 months) and 9.8 months (95% CI, 3.5 to 16.0 months), respectively. The main hematologic toxicity was anemia, which was observed in 119 cycles (56.7%). Grade 3/4 neutropenia was observed in 32 cycles (15.2%). The main non-hematologic toxicity was constipation, which was observed in 91 cycles (46.2%). Peripheral neuropathy occurred in 71 cycles (33.8%); all cases were grade 1 or 2. No treatment-related deaths were reported.
CONCLUSION
This study showed that combination chemotherapy with oxaliplatin, 5-FU, and FA is an active and well-tolerated regimen as first-line treatment in patients with metastatic or recurrent gastric cancer.

Citations

Citations to this article as recorded by  
  • Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer
    Farhad Shahi, Mojtaba Gorji, Mehrdad Payandeh, Hamid Rezvani, Mohammad Vaezi, Sharareh Seifi, Alireza Baari, Reza Khalili-Dizaji, Seyed Mehdi Hashemi, Saeid Salimi, Hosein Kamranzadeh, Babak Shazad, Sina Salari, Davoud Oulad Dameshghi, Mehdi Sarkheil, Meh
    Current Therapeutic Research.2022; 96: 100657.     CrossRef
  • Quantitative proteomic analysis of oxaliplatin induced peripheral neurotoxicity
    Linlin Yang, Hua Wang, Wanting Lu, Gangqi Yang, Zian Lin, Ruibing Chen, Hongyan Li
    Journal of Proteomics.2022; 266: 104682.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer
    H Liu, J Lu, Y Hua, P Zhang, Z Liang, L Ruan, C Lian, H Shi, K Chen, Z Tu
    Cell Death & Disease.2015; 6(1): e1595.     CrossRef
  • Oxaliplatin induced-neuropathy in digestive tumors
    María Sereno, Gerardo Gutiérrez-Gutiérrez, César Gómez-Raposo, Miriam López-Gómez, Maria Merino-Salvador, Francisco Zambrana Tébar, Cristina Rodriguez-Antona, Enrique Casado
    Critical Reviews in Oncology/Hematology.2014; 89(1): 166.     CrossRef
  • Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity ofBCL-2family gene members in stomach cancer cells
    Dimitra Florou, Christos Patsis, Alexandros Ardavanis, Andreas Scorilas
    Cancer Biology & Therapy.2013; 14(7): 587.     CrossRef
  • The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents
    Dimitra Florou, Konstantinos Mavridis, Andreas Scorilas
    Tumor Biology.2012; 33(6): 2069.     CrossRef
  • 10,752 View
  • 59 Download
  • 7 Crossref
Close layer
Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
Han Jo Kim, Kyoung Ha Kim, Jina Yun, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Do-Jin Kim, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2011;43(1):19-23.   Published online March 31, 2011
DOI: https://doi.org/10.4143/crt.2011.43.1.19
AbstractAbstract PDFPubReaderePub
PURPOSE
This phase II clinical trial was conducted to evaluate the activity and safety of a combination treatment of paclitaxel (Genexol(R)) plus carboplatin in patients with advanced non-small cell lung cancer.
MATERIALS AND METHODS
Chemotherapy-naive patients having histologically confirmed advanced or metastatic non-small cell lung cancer were enrolled. Genexol(R) was administered at 225 mg/m2 intravenous (IV) infusion over 3 hours, followed by carboplatin (area under the concentration-time curve=6) IV on day 1 every 3 weeks.
RESULTS
Twenty-eight patients were enrolled between January 2003 and January 2005. A total of 110 cycles of chemotherapy were given. The median number of chemotherapy cycles was 4. A total of 25 study patients were evaluable. On an intent-to-treat basis, there were ten partial responses (response rate 35.7%). The median time-to-progression was 3.2 months (95% confidence interval [CI], 1.5 to 4.9) and the median overall survival was 8.2 months (95% CI, 4.1 to 12.3). The main hematologic grade 3/4 toxicity was neutropenia, which was observed in 14 (50.0%) patients. The main non-hematologic toxicity was peripheral neuropathy, which was observed in 12 patients (42.9%). Grade 3/4 neuropathy occurred in 8 patients (28.6%) and three patients discontinued treatment because of neuropathy.
CONCLUSION
In this trial, the combination of Genexol(R) and carboplatin showed significant activity as first line treatment for patients with advanced or metastatic non-small cell lung cancer. However, a modest dose reduction of Genexol(R) is needed due to sensory neuropathy.

Citations

Citations to this article as recorded by  
  • Therapeutic Nanoparticles: Advantages and Toxicity
    Dr. Lata Ramrakhiani
    Indian Journal of Environment Engineering.2022; 2(1): 19.     CrossRef
  • Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells
    Wei-Chiao Huang, Pierre-Alain Burnouf, Yu-Cheng Su, Bing-Mae Chen, Kuo-Hsiang Chuang, Chia-Wei Lee, Pei-Kuen Wei, Tian-Lu Cheng, Steve R. Roffler
    ACS Nano.2016; 10(1): 648.     CrossRef
  • Nanotechnology applications in thoracic surgery
    Sophie C. Hofferberth, Mark W. Grinstaff, Yolonda L. Colson
    European Journal of Cardio-Thoracic Surgery.2016; 50(1): 6.     CrossRef
  • Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
    Nazila Kamaly, Basit Yameen, Jun Wu, Omid C. Farokhzad
    Chemical Reviews.2016; 116(4): 2602.     CrossRef
  • Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model
    Elham Ajorlou, Ahmad Yari Khosroushahi, Hamid Yeganeh
    Pharmaceutical Research.2016; 33(6): 1426.     CrossRef
  • Reinvention of chemotherapy
    Tu Nguyen-Ngoc, Eric Raymond
    Current Opinion in Oncology.2015; 27(3): 232.     CrossRef
  • Lung Cancer Nanomedicine: Potentials and Pitfalls
    Deniz Ali Bölükbas, Silke Meiners
    Nanomedicine.2015; 10(21): 3203.     CrossRef
  • Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
    Susana Patricia Egusquiaguirre, Manuela Igartua, Rosa María Hernández, José Luis Pedraz
    Clinical and Translational Oncology.2012; 14(2): 83.     CrossRef
  • Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities
    Ahmad Yari Khosroushahi, Hossein Naderi-Manesh, Hamid Yeganeh, Jaleh Barar, Yadollah Omidi
    Journal of Nanobiotechnology.2012;[Epub]     CrossRef
  • Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
    Twan Lammers, Fabian Kiessling, Wim E. Hennink, Gert Storm
    Journal of Controlled Release.2012; 161(2): 175.     CrossRef
  • 11,162 View
  • 69 Download
  • 10 Crossref
Close layer
Case Report
Mixed Testicular Germ Cell Tumor Presenting as Metastatic Pure Choriocarcinoma Involving Multiple Lung Metastases That Was Effectively Treated with High-dose Chemotherapy
Sang-Cheol Lee, Kyoung Ha Kim, Sung Han Kim, Nam Su Lee, Hee Sook Park, Jong-Ho Won
Cancer Res Treat. 2009;41(4):229-232.   Published online December 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.4.229
AbstractAbstract PDFPubReaderePub

Choriocarcinoma in the testis is very rare, and it represents less than 1% (0.3%) of all the testicular germ cell tumors. It is a particularly aggressive variant of non-seminoma tumor, which is characterized by a high serum β-HCG level and multiple lung metastases. The optimal management for this disease remains undefined. We report here on a case of choriocarcinoma with multiple lung metastases, and the patient has achieved continuous remission for 2 years after combination chemotherapy of BEP (bleomycin, etoposide and cisplatin) and sequential high-dose chemotherapy with autologous peripheral stem cell rescue.

Citations

Citations to this article as recorded by  
  • Testicular Mixed Germ Cell Tumor Presenting with Upper Gastrointestinal Bleeding: A Case Report
    Emilija Nikolovska Trpchevska, Beti Todorovska, Magdalena Bogdanovska Todorovska, Meri Trajkovska, Dafina Nikolova, Darko Dzambaz, Gjorgji Deriban, Fana Licoska-Josifovikj
    PRILOZI.2023; 44(2): 47.     CrossRef
  • Gastrointestinal Bleeding Secondary to Metastatic Duodenal Choriocarcinoma in a Patient with Concomitant Peptic Ulcer Disease
    Ahmed Elfiky, Asmaa Mokhtar, Mira Alsheikh, Hassan Almoussawi, Stephen Mulrooney, Haruhiko Sugimura
    Case Reports in Gastrointestinal Medicine.2021; 2021: 1.     CrossRef
  • Gastrointestinal Bleeding with Hemodynamic Repercussion due to a Gastric Metastatic Lesion of a Testicular Choriocarcinoma in a Previously Asymptomatic Young Adult
    Omar Al Salman, Fahad Malik, Shashank Trivedi, Marwah Alchalabi, Shobhana Chaudhari
    GE - Portuguese Journal of Gastroenterology.2020; 27(3): 212.     CrossRef
  • Choriocarcinomas May Be Presented with Abnormal Manifestations
    Alpaslan Tanoglu, Tolga Duzenli
    International Journal of Cancer Management.2017;[Epub]     CrossRef
  • Metastatic Testicular Choriocarcinoma: A Rare Cause of Upper GI Bleeding
    Kirsty Lowe, Jacqueline Paterson, Sharon Armstrong, Shaun Walsh, Max Groome, Craig Mowat
    ACG Case Reports Journal.2016; 3(1): 36.     CrossRef
  • Metastatic choriocarcinoma induced separate simultaneous intracerebral haemorrhages: a very rare occurrence and its novel association with Klinefelter syndrome
    Maximilian Olavi Joret, Robert M Starke, John Scotter, Peter Heppner
    BMJ Case Reports.2015; : bcr2015212777.     CrossRef
  • Contrast-Enhanced Ultrasonography of the Testes
    Ounali S. Jaffer, Paul S. Sidhu
    Ultrasound Clinics.2013; 8(4): 509.     CrossRef
  • Multiparametric ultrasonography of the testicles
    Tobias De Zordo, Daniel Stronegger, Leo Pallwein-Prettner, Chris J. Harvey, Germar Pinggera, Werner Jaschke, Friedrich Aigner, Ferdinand Frauscher
    Nature Reviews Urology.2013; 10(3): 135.     CrossRef
  • A Case of Gastrointestinal Bleeding due to Duodenal Metastasis from a Testicular Choriocarcinoma
    Magdalene Vardaros, Miral Subhani, Kaleem Rizvon, Vladimir Gotlieb, Paul Mustacchia, Lester Freedman, Vikas Garg, Jaspreet Singh, Ghulam Siddiqui
    Journal of Gastrointestinal Cancer.2013; 44(2): 234.     CrossRef
  • Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer
    R. Koster, M.A.T.M. van Vugt, H. Timmer-Bosscha, J.A. Gietema, S. de Jong
    Expert Reviews in Molecular Medicine.2013;[Epub]     CrossRef
  • 14,918 View
  • 69 Download
  • 10 Crossref
Close layer
Original Article
General
Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
Jung Sun Kim, Jung Hye Kwon, Sun Young Rha, Sang-Cheol Lee, Yoon Jung Chang, In-Sun Kwon, Kyung Han You, Ho Young Yoon
Cancer Res Treat. 2023;55(2):442-451.
DOI: https://doi.org/10.4143/crt.2022.1483
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
An increasing number of patients with cancers are interested in complementary and alternative medicine (CAM), which lacks scientific evidence. This study aimed to determine how CAM was used and how media affected patients in online cancer support groups (OCSG).
Materials and Methods
Between August 18 and September 12, 2021, an online survey was conducted among the members of OCSG. The survey consisted of five parts: baseline characteristics, attitudes toward and experience with CAM, source of information and reliabilities, experience with anthelmintics, and online health information literacy and usage.
Results
Among the 644 responders, a total of 221 patients with cancer completed the survey, and 78.2% (173/221) used CAM. The users’ median age was 52 years; 46.8% were males, and 43.9% had metastatic disease. Fifty-three CAM users (30.6%) discussed their physicians about CAM. In addition, 16.2% (28/173) of CAM users had the experience of anthelmintics. The use of anthelmintics in patients with cancers was associated with younger age (odds ratio [OR], 0.89; 95% confidence interval [CI], 0.84 to 0.95), metastatic disease (OR, 10.88; 95% CI, 3.39 to 34.86), previous exposure to CAM information (OR, 5.57; 95% CI, 1.01 to 30.72), experience with more types of CAM (OR, 1.98; 95% CI, 1.29 to 3.05), and side effects (OR, 5.10; 95% CI 1.46 to 17.75).
Conclusion
Use of anthelmintics, a CAM of which information is widespread online, is affected by several factors. This study will provide essential information for developing a CAM management strategy in this digital age.

Citations

Citations to this article as recorded by  
  • Uso de medicina alternativa en pacientes oncológicos en la ciudad de Neiva (Colombia)
    Nicolás Martínez-Ramos, Carolina Mariño, Laura Camila Olaya-SanMiguel, Raúl Murillo
    Universitas Médica.2024; 65: 1.     CrossRef
  • Factors associated with nursing practice for cancer patients using complementary and alternative medicine
    Junko Kusunoki, Sumie Ikezaki, Tomoko Majima
    Collegian.2023; 30(5): 668.     CrossRef
  • 4,575 View
  • 148 Download
  • 2 Web of Science
  • 2 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP